In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes

References

• Alonso-Castro AJ, Ortiz-Sanchez E, Garcia-Regalado A, Ruiz G, Nunez-Martinez JM, Gonzalez-Sanchez I, Quintanar-Jurado V, Morales-Sanchez E, Dominguez F, Lopez-Toledo G, et al. 2013. Kaempferitrin induces apoptosis via intrinsic pathway in HeLa cells and exerts antitumor effects. J Ethnopharmacol. 145(2):476–489.
   PubMed Web of Science ®Google Scholar
• Da Silva D, Casanova LM, Marcondes MC, Espindola-Netto JM, Paixao LP, De Melo GO, Zancan P, Sola-Penna M, Costa SS. 2014. Antidiabetic activity of Sedum dendroideum: metabolic enzymes as putative targets for the bioactive flavonoid kaempferitrin. IUBMB Life. 66(5):361–370.
   PubMed Web of Science ®Google Scholar
• Dong G, Zhou Y, Song X. 2018. In vitro inhibitory effects of bergenin on human liver cytochrome P450 enzymes. Pharm Biol. 56(1):620–625.
   PubMed Web of Science ®Google Scholar
• Ericsson T, Sundell J, Torkelsson A, Hoffmann KJ, Ashton M. 2014. Effects of artemisinin antimalarials on cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies. Xenobiotica. 44(7):615–626.
   PubMed Web of Science ®Google Scholar
• Fang ZZ, Zhang YY, Ge GB, Huo H, Liang SC, Yang L. 2010. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol. 69(2):193–199.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Trujano ME, Dominguez F, Perez-Ortega G, Aguillon M, Martinez-Vargas D, Almazan-Alvarado S, Martinez A. 2017. Justicia spicigera Schltdl. and kaempferitrin as potential anticonvulsant natural products. Biomed Pharmacother. 92:240–248.
   PubMed Web of Science ®Google Scholar
• Hamzah AS, Lajis NH, Sargent MV. 1994. Kaempferitrin from the leaves of Hedyotis verticillata and its biological activity. Planta Med. 60(4):388–389.
   PubMed Web of Science ®Google Scholar
• Hu X, Huang W, Yang Y. 2015. Cytochrome P450 isoenzymes in rat and human liver microsomes associate with the metabolism of total coumarins in Fructus Cnidii. Eur J Drug Metab Pharmacokinet. 40(4):373–377.
   PubMed Web of Science ®Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. 1998. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol. 38:461–499.
   PubMed Web of Science ®Google Scholar
• Jeong HU, Kong TY, Kwon SS, Hong SW, Yeon SH, Choi JH, Lee JY, Cho YY, Lee HS. 2013. Effect of honokiol on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules. 18(9):10681–10693.
   PubMed Web of Science ®Google Scholar
• Jiang W, Wang R, Liu D, Zuo M, Zhao C, Zhang T, Li W. 2018. Protective effects of kaempferitrin on advanced glycation end products induce mesangial cell apoptosis and oxidative stress. IJMS. 19(11):3334.
   Web of Science ®Google Scholar
• Jorge AP, Horst H, de Sousa E, Pizzolatti MG, Silva FR. 2004. Insulinomimetic effects of kaempferitrin on glycaemia and on 14C-glucose uptake in rat soleus muscle. Chem Biol Interact. 149(2–3):89–96.
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Unadkat JD. 2010. Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution. Drug Metab Dispos. 38(11):1926–1933.
   PubMed Web of Science ®Google Scholar
• Ku WC, Chang YL, Wu SF, Shih HN, Tzeng YM, Kuo HR, Chang KM, Agrawal DC, Liu BL, Chang CA, et al. 2017. A comparative proteomic study of secretomes in kaempferitrin-treated CTX TNA2 astrocytic cells. Phytomedicine. 36:137–144.
   PubMed Web of Science ®Google Scholar
• Lang J, Li W, Zhao J, Wang K, Chen D. 2016. Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes. Xenobiotica. 47(10):849–855.
   Web of Science ®Google Scholar
• Li AP. 2001. Screening for human ADME/Tox drug properties in drug discovery. Drug Discovery Today. 6(7):357–366.
   PubMed Web of Science ®Google Scholar
• Lim YP, Chen WC, Cheng CH, Ma WC, Lin YH, Chen CY, Hung DZ, Chen JJ, Yokoi T, Nakajima M, et al. 2014. Inhibition of cytochrome P450 2C9 expression and activity in vitro by allyl isothiocyanate. Planta Med. 80(13):1097–1106.
   PubMed Web of Science ®Google Scholar
• Liu L, Sun S, Rui H, Li X. 2017. In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes. Pharm Biol. 55(1):1868–1874.
   PubMed Web of Science ®Google Scholar
• Liu T, Qian G, Wang W, Zhang Y. 2015. Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole. Eur J Drug Metab Pharmacokinet. 40(2):235–238.
   PubMed Web of Science ®Google Scholar
• Pandit S, Mukherjee PK, Ponnusankar S, Venkatesh M, Srikanth N. 2011. Metabolism mediated interaction of α-asarone and Acorus calamus with CYP3A4 and CYP2D6 . Fitoterapia. 82(3):369–374.
   PubMed Web of Science ®Google Scholar
• Qi XY, Liang SC, Ge GB, Liu Y, Dong PP, Zhang JW, Wang AX, Hou J, Zhu LL, Yang L, et al. 2013. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol. 56:392–397.
   PubMed Web of Science ®Google Scholar
• Shimada T, Mimura M, Inoue K, Nakamura S, Oda H, Ohmori S, Yamazaki H. 1997. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol. 71(6):401–408.
   PubMed Web of Science ®Google Scholar
• Singh AP, Pant MC, Ruwali M, Shah PP, Prasad R, Mathur N, Parmar D. 2010. Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer Biomark. 8(6):351–359.
   PubMed Web of Science ®Google Scholar
• Song YQ, Weng ZM, Dou TY, Finel M, Wang YQ, Ding LL, Jin Q, Wang DD, Fang SQ, Cao YF, et al. 2019. Inhibition of human carboxylesterases by magnolol: Kinetic analyses and mechanism. Chem-Biol Interact. 308:339–349.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao Q. 2019. Kaempferitrin inhibits proliferation, induces apoptosis, and ameliorates inflammation in human rheumatoid arthritis fibroblast-like synoviocytes. Phytother Res. 33(6):1726–1735.
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Stevens JC. 1992. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 22(1):1–21.
   PubMed Web of Science ®Google Scholar
• Yan Z, Caldwell GW. 2001. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr Top Med Chem. 1(5):403–425.
   PubMedGoogle Scholar
• Zhang H, Ya G, Rui H. 2017. Inhibitory effects of triptolide on human liver cytochrome P450 enzymes and P-glycoprotein. Eur J Drug Metab Pharmacokinet. 42(1):89–98.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li C, Zhang J, Zhang F. 2019. In vitro inhibitory effects of sophocarpine on human liver cytochrome P450 enzymes. Xenobiotica. 49(10):1127–1132.
   PubMed Web of Science ®Google Scholar
• Zhang JW, Liu Y, Cheng J, Li W, Ma H, Liu HT, Sun J, Wang LM, He YQ, Wang Y, et al. 2007. Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharm Sci. 10(4):496–503.
   PubMed Web of Science ®Google Scholar
• Zhang QH, Hu JP, Wang BL, Li Y. 2012. Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 14(4):382–395.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Li SC, Huang M, Chen X, Li X, Zhang Q, Paxton JW. 2004. Predicting pharmacokinetic herb-drug interactions. Drug Metabol Drug Interact. 20(3):143–158.
   PubMedGoogle Scholar
• Zhou SF. 2008. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 9(4):310–322.
   PubMed Web of Science ®Google Scholar